Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY Correspondence
| Authors: | Mian, H.; Martin, T. G.; Pond, G. R.; Asoori, S.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Abdallah, N.; Chhabra, S.; Parrondo, R.; Ailawadhi, S.; Dimopoulos, M. A.; Yong, K.; Durie, B. G. M.; Usmani, S. Z.; Lin, Y.; Tan, C. R. |
| Title: | Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY |
| Keywords: | adult; treatment response; aged; major clinical study; overall survival; neutropenia; side effect; cancer patient; neurotoxicity; outcome assessment; follow up; cancer immunotherapy; progression free survival; cohort analysis; relapse; creatinine; data base; retrospective study; age; immunotherapy; bone marrow biopsy; toxicity testing; lactate dehydrogenase; disease duration; drug therapy; infection control; disease exacerbation; therapy; myeloma; creatinine clearance; pathological complete response; clinical outcome; cytokine release syndrome; overall response rate; frailty; cancer prognosis; international staging system; charlson comorbidity index; very elderly; human; male; female; article; extramedullary disease; ecog performance status; teclistamab; special situation for pharmacovigilance; simplified frailty index |
| Journal Title: | Leukemia |
| Volume: | 39 |
| Issue: | 5 |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2025-05-01 |
| Start Page: | 1252 |
| End Page: | 1255 |
| Language: | English |
| DOI: | 10.1038/s41375-025-02552-3 |
| PUBMED: | 40113913 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work